{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:29:24Z","timestamp":1787164164640,"version":"build-2736575974"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1097\/mbc.0b013e3280100d1e","type":"journal-article","created":{"date-parts":[[2006,11,9]],"date-time":"2006-11-09T04:34:50Z","timestamp":1163046890000},"page":"615-619","source":"Crossref","is-referenced-by-count":33,"title":["The use of recombinant activated factor VII in congenital and acquired von Willebrand disease"],"prefix":"10.1097","volume":"17","author":[{"given":"Massimo","family":"Franchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Veneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00001721-199803000-00002","article-title":"Clinical experience with recombinant factor VIIa","volume":"9","author":"Lusher","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0955-3886(98)00026-5","article-title":"Clinical use of recombinant FVIIa (rFVIIa)","volume":"19","author":"Hedner","year":"1998","journal-title":"Transfus Sci"},{"issue":"Suppl 1","key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001721-200004001-00005","article-title":"Overall experience with Novoseven\u00ae","volume":"11","author":"N\u00e8grier","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2001-16890","article-title":"Recombinant activated factor VII (rFVIIa): characterization, manufacturing and clinical development","volume":"27","author":"Jurlander","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1537-2995.2002.00017.x","article-title":"Potential role for rFVIIa in transfusion medicine","volume":"42","author":"Hedner","year":"2002","journal-title":"Transfusion"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1160\/TH05-01-0032","article-title":"Recombinant factor VIIa An update on its clinical use","volume":"93","author":"Franchini","year":"2005","journal-title":"Thromb Haemost"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.moh.0000135405.29702.3c","article-title":"Recombinant activated factor VIII for non-hemophiliac bleeding patients","volume":"11","author":"Uhlmann","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/j.1537-2995.2004.04052.x","article-title":"Transfusion medicine service policies for recombinant factor VIIa administration","volume":"44","author":"Goodnough","year":"2004","journal-title":"Transfusion"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.blre.2003.12.003","article-title":"\u2018Off-license\u2019 use of recombinant activated factor VII","volume":"18","author":"Ghorashian","year":"2004","journal-title":"Blood Rev"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1160\/TH04-03-0163","article-title":"The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics","volume":"92","author":"Mathew","year":"2004","journal-title":"Thromb Haemost"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2004-06-2223","article-title":"The use of recombinant factor VIIa in the treatment of bleeding disorders","volume":"104","author":"Roberts","year":"2004","journal-title":"Blood"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/bja\/aei094","article-title":"Recombinant factor VIIa for life-threatening post-partum haemorrhage","volume":"94","author":"Ahonen","year":"2005","journal-title":"Br J Anaesth"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0268-960X(03)90000-2","article-title":"A cell-based model of haemostasis","volume":"17","author":"Hoffman","year":"2003","journal-title":"Blood Rev"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high-dose factor VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.1074\/jbc.270.24.14477","article-title":"Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor","volume":"270","author":"Bajzar","year":"1995","journal-title":"J Biol Chem"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood.V91.12.4581","article-title":"Blood coagulation in hemophilia A and hemophilia C","volume":"91","author":"Cawthern","year":"1998","journal-title":"Blood"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1046\/j.1538-7836.2003.00225.x","article-title":"Mechanism of action of recombinant factor VIIa","volume":"1","author":"Lisman","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/j.1538-7836.2004.01015.x","article-title":"Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets","volume":"2","author":"Gabriel","year":"2004","journal-title":"J Thromb Haemost"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1172\/JCI116691","article-title":"The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor","volume":"92","author":"ten Cate","year":"1993","journal-title":"J Clin Invest"},{"key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1046\/j.1538-7836.2003.00181.x","article-title":"How factor VIIa works in hemophilia","volume":"1","author":"Butenas","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood.V99.1.175","article-title":"Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A","volume":"99","author":"Lisman","year":"2002","journal-title":"Blood"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1538-7836.2005.01227.x","article-title":"Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count","volume":"3","author":"Lisman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R23-2-20210203","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1055\/s-0037-1613132","article-title":"Factor VIIa induced release of von Willebrand factor from human umbilical vein endothelial cells by a tyrosine kinase dependent pathway","volume":"87","author":"Brown","year":"2002","journal-title":"Thromb Haemost"},{"key":"R24-2-20210203","first-page":"94","article-title":"von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman","year":"2003","journal-title":"Haematologica"},{"issue":"Suppl 4","key":"R25-2-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2516.2004.00991.x","article-title":"Clinical diagnosis of von Willebrand disease","volume":"10","author":"Federici","year":"2004","journal-title":"Haemophilia"},{"key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2516.2004.00894.x","article-title":"The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization","volume":"10","author":"Laffan","year":"2004","journal-title":"Haemophilia"},{"key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2516.2002.00672.x","article-title":"Italian Association of Hemophilia Centers (AICE) Guidelines for the diagnosis and management of von Willebrand disease in Italy","volume":"8","author":"Federici","year":"2002","journal-title":"Haemophilia"},{"key":"R28-2-20210203","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood.V97.7.1915","article-title":"How I treat patients with von Willebrand disease","volume":"97","author":"Mannnucci","year":"2001","journal-title":"Blood"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1600-0609.1987.tb01458.x","article-title":"Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor","volume":"39","author":"Mannucci","year":"1987","journal-title":"Eur J Haematol"},{"key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/00001721-199304060-00020","article-title":"Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors","volume":"4","author":"Majumdar","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"Suppl 1","key":"R31-2-20210203","first-page":"150","article-title":"Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor","volume":"26","author":"Ciavarella","year":"1996","journal-title":"Haemostasis"},{"issue":"Suppl","key":"R32-2-20210203","first-page":"84","article-title":"Efficacy of recombinant factor VIIa (NovoSeven) in patients affected by von Willebrand disease type III with alloantibodies against von Willebrand factor in oral surgery [abstract.]","volume":"78","author":"Schiavoni","year":"1997","journal-title":"Thromb Haemost"},{"key":"R33-2-20210203","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0037-1613878","article-title":"Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor","volume":"83","author":"Grossmann","year":"2000","journal-title":"Thromb Haemost"},{"key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1538-7836.2003.00009.x","article-title":"Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease","volume":"1","author":"Boyer-Neumann","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R35-2-20210203","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s10353-005-0192-x","article-title":"Treatment of acute hemorrhage in a patient with type 3 von Will brand's disease and alloantibodies against von Will brand factor with recombinant activated factor VII","volume":"37","author":"Dietrich","year":"2005","journal-title":"Eur Surg"},{"key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1309\/D0G0C96V05CJ5B4J","article-title":"Recombinant factor VIIa in the treatment of bleeding","volume":"121","author":"Midathada","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"R37-2-20210203","first-page":"60","article-title":"Recombinant factor VIIa (NovoSeven) for post-prostatectomy hemorrhage in a patient with type I von Willebrand disease.","volume":"68","author":"Tarantino","year":"200","journal-title":"Am J Hematol"},{"key":"R38-2-20210203","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00001721-200104000-00008","article-title":"Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrands disease, controlled with recombinant factor VIIa.","volume":"12","author":"Meijer","year":"200","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R39-2-20210203","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.transci.2004.05.002","article-title":"Recombinant coagulation factor VIIa in the management of bleeding in patients with von Willebrand disease type 2A","volume":"31","author":"Matyskova","year":"2004","journal-title":"Transfus Apher Sci"},{"key":"R40-2-20210203","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/01.mbc.0000224852.42625.0d","article-title":"The use of recombinant-activated factor VII in von Willebrand disease: a case series","volume":"17","author":"von Depka","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R41-2-20210203","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00001721-200408000-00010","article-title":"Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease","volume":"15","author":"Basso","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R42-2-20210203","first-page":"348","article-title":"Auto-antibody against inhibitors of von Willebrand factor protein","volume":"9","author":"Cohen","year":"1996","journal-title":"Bailliere's Clin Haematol"},{"key":"R43-2-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1096-8652(199702)54:2<139::AID-AJH7>3.0.CO;2-Y","article-title":"Acquired von Willebrand disease: a concise review","volume":"54","author":"Rinder","year":"1997","journal-title":"Am J Haematol"},{"key":"R44-2-20210203","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0002-9343(97)00239-8","article-title":"Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis and treatment","volume":"103","author":"Tefferi","year":"1997","journal-title":"Am J Med"},{"key":"R45-2-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-0037-1613993","article-title":"Acquired von Willebrand syndrome: from pathophysiology to management","volume":"84","author":"Veyradier","year":"2000","journal-title":"Thromb Haemost"},{"key":"R46-2-20210203","doi-asserted-by":"crossref","first-page":"-149","DOI":"10.1023\/B:THRO.0000011369.70824.e6","article-title":"Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.","volume":"15","author":"Mohri","year":"2003","journal-title":"J Thromb Thrombolysis"},{"key":"R47-2-20210203","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-0037-1619606","article-title":"Acquired von Willebrand syndrome 2004: international registry","volume":"24","author":"Federici","year":"2004","journal-title":"H\u00e4mostaseologie"},{"key":"R48-2-20210203","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/beha.2001.0141","article-title":"Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management","volume":"14","author":"Michiels","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"R49-2-20210203","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ajh.1060","article-title":"Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease","volume":"66","author":"Friedrich","year":"2001","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"R50-2-20210203","first-page":"1129","article-title":"Recombinant factor VIIa as a hemostatic agent in acquired von Willebrand disease [abstract]","volume":"1","author":"Perez-Montes","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R51-2-20210203","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1055\/s-0037-1613738","article-title":"A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy","volume":"92","author":"Smaradottir","year":"2004","journal-title":"Thromb Haemost"}],"container-title":["Blood Coagulation &amp; Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001721-200611000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:45:40Z","timestamp":1786031140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-200611000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e3280100d1e","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}